Government Bioscience Grants

UPDATED MONTHLY

September 10, 2021

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

PUBLISHED BY

G2G CONSULTING

Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com

www.G2Gconsulting.com

@G2Gconsulting

www.G2Gconsulting.com/bioscience-corner

GBG Report

Updated Monthly

September 10, 2021

September 17, 2021 from 10:00am-10:30 am EDT – Join us for G2G's Monthly GBG Report and Highlights Call & Screen Share when we will take a closer look at funding opportunities listed below and close with Q&A. Click here to register.

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			AGING (4)			
1.	Healthy Aging: Optimizing Physical and Mental Functioning Across the Aging Continuum -- Cycle 3 2021 (PCORI)	N/A	PCORI is seeking to fund high-quality, CER projects that focus on optimizing physical and mental functioning for community-dwelling older adults and their caregivers. The Healthy Aging Targeted PFA will solicit applications for CER studies that focus on different phases of the aging continuum and aim to achieve one or more of the following four goals: Maintaining function and independence; Facilitating chronic disease management; Supporting individuals with significant functional impairment; Reducing caregiving burden and improving quality of life.	Letter of intent due: 10/5/21 Proposal due: 1/11/22	Up to $5 million, for up to 5 years	https://www.pcori.org/funding-opportunities/announcement/healthy-aging-optimizing-physical-mental-functioning-across-aging-continuum-cycle-3-2021
2.	NOSI: Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research (NIH/NIA)	NOT-AG-21-020	There are 2 grants within this NOSI. The goal of this NOSI is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan, (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health (the hallmarks of aging).	Proposal due: 10/5/21 10/16/21	Up to $275,000 Dependent upon award mechanism	https://grants.nih.gov/grants/guide/notice-files/NOT-AG-21-020.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			AGING			
3.	Detecting Cognitive Impairment, Including Dementia, in Primary Care and Other Everyday Clinical Settings for the General Public and Health Equity, Pragmatic Clinical Trials (U01 Clinical Trial Required) (NIH/NINDS/ NIA)	RFA-NS-22-009	This FOA invites pragmatic clinical trial applications to test paradigms designed to address the unmet need to detect cognitive impairment, including dementia, in large and diverse populations seen in primary care across the United States when a patient, relative, or care provider indicates concern. Applications must propose pragmatic clinical trials to test paradigms to detect cognitive impairment, including dementia, with adequate power in up to 3 populations including at least two specified populations that experience health disparities.	Letter of intent due: 9/10/21 Proposal due: 11/10/21	Up to $1 million per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-009.html
			AIR FORCE OFFICE OF SCIENTIFIC RESEARCH (2)			
4.	Air Force Office of Scientific Research Broad Agency Announcement (DoD/Air Force)	FA9550-18-S-0003	This BAA's focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific branches: Engineering and Information Sciences (RTA) and Physical and Biological Sciences (RTB). Research topics in the Chemistry and Biological sciences categories include Biophysics; Human Performance and Biosystems; Mechanics of Multifunctional Materials and Microsystems; Molecular Dynamics and Theoretical Chemistry; Natural Materials, Systems, and Extremophiles; and Organic Materials Chemistry. For a full list of applicable research topics, see full solicitation.	Proposals accepted on a rolling basis	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=305996 (Full Announcement in Related Documents Tab)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			AIR FORCE OFFICE OF SCIENTIFIC RESEARCH			
5.	Research Interests of the Air Force Office of Scientific Research (DoD/Air Force)	FA9550-21-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are managed in within four teams under two scientific Departments: Engineering and Information Science & Physical and Biological Sciences. The Engineering and Complex Systems team leads the discovery and development of the fundamental and integrated science that advances future air and space flight. The Information and Networks Team is organized to support many U.S. Air Force and Space Force priority areas including autonomy, space situational awareness, and cyber security. The Physical Sciences Team leads the discovery and transition of foundational physical science to enable air, space, and cyber power. The Chemistry and Biological Sciences Team is responsible for research activities in fundamental chemistry, biology, mechanics, and biophysics research.	White papers accepted on a rolling basis	Dependent upon proposal, for up to 5 years	https://www.grants.gov/web/grants/view-opportunity.html?oppId=334084 (Full Announcement in Related Documents Tab)
			AIR FORCE RESEARCH LABORATORY (1)			
6.	Collaborations for Innovative Research on Aerospace Structure (CIRAS) BAA (DoD/AFRL)	FA865021S2205	The Aerospace Vehicles Division (RQV), Aerospace Systems Directorate (RQ), Air Force Research Laboratory (AFRL), is soliciting research in aircraft structural design, analysis, and experimentation, specifically in the following areas: 1. Innovative structural concepts for reducing weight and/or improving performance 2. Generation of realistic load and environmental spectra Advanced structural design and analysis methods	White papers accepted on a rolling basis Proposal solicited by invitation	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=333471 (Full Announcement in Related Documents Tab)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			ALZHEIMER'S DISEASE (5)			
7.	Dementia Care and Caregiver Support Intervention Research (R01 Clinical Trial Required) Pragmatic Trials for Dementia Care and Caregiver Support (R61/R33 – Clinical Trial Required) (NIH/NIA)	PAR-21-307 (R01) PAR-21-308 (R61/R33)	The R01 FOA solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with AD and ADRD and of those providing their care. The NIH Stage Model offers a framework to: (1) support development of efficacious interventions that are defined by their principles; and (2) ensure that these efficacious interventions can be administered in the community or in health systems with fidelity to the intervention's principles. This includes the development, testing, and validation of scalable training materials and procedures so that these interventions can be delivered with fidelity in community settings or health systems. Settings can include the home, community, or formal care settings, such as nursing homes, assisted living facilities, nursing and rehabilitation centers, hospitals, adult day care, and specialized hospice settings. The overarching purpose of this FOA is to help to lay the groundwork for real-world implementation of AD/ADRD care and caregiving interventions.	Letter of intent due: 1/10/22 9/11/22 1/10/23 Proposal due: 2/10/22 10/11/22 2/10/23	Dependent upon proposal, for up to 5 years (R01) Up to $500,000, for up to 2 years (R61) Over $500,000 per year, for up to 4 years (R33)	https://grants.nih.gov/grants/guide/pa-files/PAR-21-307.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-21-308.html (R61/R33)
8.	NINDS AD/ADRD Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed) (NIH/NINDS /NIA)	PAR-22-022	The purpose of this FOA is to support a cohort of new and talented, independent investigators from diverse backgrounds conducting AD/ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field.	Proposal due: 10/12/21 2/12/22 6/12/22	Up to $249,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-22-022.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			ALZHEIMER'S DISEASE			
9.	Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed) (NIH/NINDS/ NIA)	PAR-22-026	This FOA is further promotes the development of novel approaches, tools, technologies, biomarkers used as tools to develop fundamental mechanistic knowledge or non-invasive imaging techniques to support the structural and functional characterization of CNS vessels in the AD/ADRDs, as well as to determine the mechanisms that lead to their dysfunction and contribute to cognitive impairment. Preclinical studies using in vitro and/or animal models of the AD/ADRDs, pilot human subjects studies in AD/ADRD patient populations, or a combination of these are appropriate for this FOA. Multidisciplinary teams with complementary expertise are encouraged to apply. Both mechanistic studies using innovative approaches and applications aimed at developing novel tools or technology specific to CNS small blood and lymphatic vessels in the AD/ADRDs will be considered within the scope of this RFA.	Proposal due: 11/8/21	Up to $499,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-22-026.html
10.	Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed) (NIH/NINDS/ NIA)	PAR-22-029	This FOA supports projects to identify cellular changes in ADRD post-mortem brain tissue across disease progression. Applicants are encouraged to propose single-nucleus transcriptomic and epigenomic studies that identify changes in neuronal, glial, or vascular cells over multiple ADRD stages, from early to mid-stage. All sequencing data and any available pre-mortem clinical data will be broadly shared with the research community.	Proposal due: 10/5/21	Up to $630,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-22-029.html
			ARMY APPLICATIONS LAB (1)			
11.	Army Applications Lab BAA for Disruptive Applications (DoD/Army)	W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch.	Proposals accepted through 5/1/24 Pre-proposal is required	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517 (Full Announcement in Related Documents Tab)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			ARMY RESEARCH LABORATORY (1)			
12.	Army Research Laboratory Broad Agency Announcement for Basic and Applied Scientific Research (DoD/Army)	W911NF-17-S-0003	The ARL BAA seeks proposals from institutions of higher education, nonprofit organizations, state and local governments, foreign organizations, foreign public entities, and for-profit organizations (i.e. large and small businesses) for research based on the following S&T campaigns: Computational Sciences, Materials Research, Sciences for Maneuver, Information Sciences, Sciences for Lethality and Protection, Human Sciences, and Assessment and Analysis. Further details are described in the ARL Technical Strategy and in the ARL S&T Campaigns located at www.arl.army.mil. These documents are subject to periodic refinements which may result in taxonomy inconsistencies.	No due dates, open until 3/31/22	Dependent upon proposal	https://www.arl.army.mil/wp-content/uploads/2019/11/arl-baa-ARL-BAA-W911NF-17-S-0003-Amendment-07-2-6-19.pdf
			ARMY RESEARCH OFFICE (2)			
13.	Army Research Office Broad Agency Announcement for Fundamental Research (DoD/Army)	W911NF-17-S-0002-07	The purpose of this BAA is to solicit research proposals in the engineering, physical, life, and information sciences for submission to the Army Research Office (ARO) for consideration for possible funding. ARL has an overarching technical strategy to support Strategic Land Power Dominance for the Army of 2030 and beyond. The strategy is based on seven Technical Competencies: Computational Sciences, Ballistics Sciences, Materials & Manufacturing Sciences, Protection Sciences, Propulsion Sciences, Network & Information Sciences and Human Sciences.	No due dates, open until 3/31/22	Dependent upon proposal	https://www.arl.army.mil/wp-content/uploads/2020/04/ARO-BAA-Amendment-7-Final.pdf
14.	Army Research Office Broad Agency Announcement Staff Research Program (DoD/Army)	W911NF20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. The staff research will be performed collaboratively with institutions external to ARO. Staff research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences, when there is an intersection with the interests and capabilities of the participating external institutions in these basic research areas.	No due dates, open until 2/19/25	Dependent upon proposal	https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (2)			
15.	Program Announcement for AI Exploration (DoD/DARPA)	DARPA-PA-21-04	DARPA seeks to invest in focused explorations of what the AI science and technologies of the future could be. DARPA's AIE program will enable exploratory research on a range of AI related topics that will be periodically solicited as AIE Opportunities through publication of Presolicitation Notices under Contract Opportunities on https://SAM.gov.	TBD	Dependent on proposal and award mechanism	https://sam.gov/opp/b04934de80af4f5b92ab51852266c8c7/view
16.	Transformative Artificial Intelligence and Machine Learning Based Strategies to Identify Determinants of Exceptional Health and Life Span (R21/R33 Clinical Trial Not Allowed) (NIH/NIA)	RFA-AG-22-022	This FOA will use the NIH Phased Innovation Award mechanism (R21/R33) to develop novel transformative artificial intelligence/machine learning (AI/ML) strategies and computer automation to integrate, extract, and interpret multi-omic data sets from human exceptional longevity cohorts and multiple non-human species that display wide variation in life span and decipher the relationships between DNA, RNA, proteins, metabolites, and other cell variables, as well as links to disease risks and exceptionally healthy aging. The investigative team(s) for this FOA is/are expected to be multi-disciplinary, encompassing expertise in AI/ML, aging biology, comparative biology, and bio/chemo informatics. Investigative teams will design/develop intelligent and innovative algorithms and novel AI/ML based computational strategies during the R21 phase, then apply the developed AI/ML tools to complex, heterogenous multi-omic data sets from exceptional healthy aging human cohorts and non-human species in the R33 phase	Letter of intent due: 9/28/21 Proposal due: 10/28/21	Up to $1.35 million, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-022.html
			AUTISM (2)			
17.	Autism Centers of Excellence (ACE): Networks and Centers (R01/P50 Clinical Trial Optional) (NIH)	RFA-HD-22-007 (R01) RFA-HD-22-008 (P50)	The ACE program is a trans-NIH initiative that supports large-scale studies on ASD. The program includes ACE Centers, which foster collaboration between teams of specialties to address major questions about ASD in depth, and ACE Networks, which consist of researchers at multiple sites, all of whom work together on a specific topic of research. The purpose of ACE program is to support research that will lead to better understanding of the causes and mechanisms underlying ASD, improved efficiency of methods of early identification and diagnosis, and more innovative and cost-effective services for individuals with ASD across their lifespan.	Letter of intent due: 10/9/21 Proposal due: 11/9/21	Up to $1.5 million per year, for up to 5 years.	https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-007.html https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-008.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			BARDA (2)			
18.	BARDA Broad Agency Announcement (HHS/BARDA)	BAA-18-100-SOL-00003	Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue. COVID-19 related Areas of Interest includes: • Diagnostic Assay for Human Coronaviruses • Diagnostic Assay for Detection of SARS-CoV-2 Virus • Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies Screening Tests at Point of Care (2-minute Time to Result)	White papers due: 10/31/21	Dependent upon proposal	https://sam.gov/opp/550c21c541ac4c5ea14a52997a84a65d/view https://www.medicalcountermeasures.gov/barda/barda-baa
19.	BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement (EZ-BAA) (HHS/BARDA)	BAA-20-100-SOL-00002	BARDA is accepting submissions through the EZ-BAA for the following AOIs, 1) Early Notification to Act, Control and Treat: seeking technologies to identify, characterize, and broadly adapt biological, biometric, behavioral and physiological signatures that can signal health security threat infections or exposures. 2) Infection Severity & Solving Sepsis: catalyzing technologies along the sepsis patient continuum with a focus on technologies that address sepsis. 5) Repurposing Drugs In Response to Chemical Threats: repurpose common therapeutics as medical counter measures and treat the symptoms associated with chemical agent exposure. 6) Beyond the Needle. The goal is to reduce the burden of traditional vaccine delivery via needle and syringe on the healthcare system and supply-chain.	No due dates, open until 2/3/23	Up to $750,000, per award	https://sam.gov/opp/f2b87e34fecf47d0a48e9b03e8e826ff/view https://drive.hhs.gov/partner.html
			BIOENGINEERING (1)			
20.	NOSI: Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue) (NIH/NHLBI)	NOT-HL-21-024	This NOSI invites discovery- and design-driven bioengineering research ideas that are important across the Institute and that are critical for future hypothesis-generating projects. It is noteworthy that this program emphasizes development, not so much efficacy, of first-generation prototypes. The NHLBI is interested in the development of new ideas for diagnostics, therapeutics, surgical technologies, computational modeling tools, smart biomaterials for self-adjusting implants, and nanotechnologies, as applied to the cardiovascular, pulmonary, non-malignant hematologic, and sleep health mission areas of the Institute.	Proposal due: 10/16/21 2/16/22 6/16/22	Up to $275,000, for up to 2 years	https://grants.nih.gov/grants/guide/notice-files/NOT-HL-21-024.html https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			BIOMOLECULAR MAPPING (3)			
21.	The Human BioMolecular Atlas Program (HuBMAP) Integration, Visualization & Engagement (HIVE) Collaboratory (OT2) (NIH Common Fund)	NOT-RM-21-031 OTA-21-012	The HuBMAP seeks to catalyze development of atlases of the human body at high resolution to transform our understanding of tissue organization and function. The HIVE will be composed of projects funded in three component areas all of which are expected to work closely together to act as the unified backbone for HuBMAP. These components are: 1) an Infrastructure Component (IC); 2) Mapping Component (MC); and 3) Tools Component (TC). The IC would be responsible for maintaining, optimizing, and scaling a reliable, accessible infrastructure for archiving and analysis of data generated initially by HuBMAP and later by the wider research community. The MC is to develop the framework for spatially mapping the data in the context of the human body, organ(s), and regions, as well as implementing novel methods to build tissue level maps that can be stitched together using multi-modal data. While the TC will focus on creating and/or using community standard methods for data analysis, processing, interpretation, and visualization of HuBMAP data.	Letter of intent due: 10/1/21 Proposal due: 12/3/21	Up to $4 million per year, for up to 5 years	https://grants.nih.gov/grants/guide/notice-files/NOT-RM-21-031.html https://commonfund.nih.gov/sites/default/files/HuBMAP-HIVE-OTA-21-012-v2-508.pdf
			CANCER (18)			
22.	Cancer Research Education Grants Program - Courses for Skills Development and Research Experiences (R25 Clinical Trial Not Allowed) (NIH/NCI)	PAR-21-278 PAR-21-279	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission. Three additional companion FOAs were listed in the Dec 2020 GBG report: PAR-21-065; 066; 067.	Proposal due: 9/25/21 1/25/22 5/25/22	Up to $300,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-278.html https://grants.nih.gov/grants/guide/pa-files/PAR-21-279.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			CANCER			
23.	NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed/ Required) (NIH/NCI)	PAR-21-295 PAR-21-296	These FOAs seek to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. PAR-21-295 supports career and research development; PAR-21-296 supports the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial.	Proposal due: 10/12/21 2/12/22 6/12/22	Up to $100,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-295.html https://grants.nih.gov/grants/guide/pa-files/PAR-21-296.html
24.	NOSI: Advancing the development of tumor site-activated small molecules (NIH/NCI)	NOT-CA-21-101	Five opportunities linked within this notice. This purpose of this NOSI is to foster a systematic effort that will leverage latest advancements in the field to address key questions that underlie the development tumor-site activated small molecules, in order to identify therapeutics with improved safety and efficacy profiles. This NOSI encourages grant applications with chemistry, biochemistry, biology, pharmacology, and computational collaborative approaches that address one or more of the research gaps as outlined.	Multiple deadlines; first available due date: 2/5/22	Dependent upon award mechanism	https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-101.html
25.	Basic Research in Cancer Health Disparities (R01/R21/R03 Clinical Trial Not Allowed) (NIH/NCI)	PAR-21-322 (R01) PAR-21-323 (R21) PAR-21-324 (R03)	These FOAs encourage grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. All grants will investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. PAR-21-322 supports research grants; PAR-21-323 supports pilot and feasibility studies; PAR-21-324 supports projects that can be carried out in a short period of time with limited resources.	Proposal due: 10/5/21 2/5/22 6/5/22 (R01) Proposal due: 10/16/21 2/16/22 6/16/22 (R21/R03)	Dependent on proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21) Up to $50,000 per year, for up to 2 years (R03)	https://grants.nih.gov/grants/guide/pa-files/PAR-21-322.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-21-323.html (R21) https://grants.nih.gov/grants/guide/pa-files/PAR-21-324.html (R03)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			CANCER			
26.	Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) (NIH/NCI)	PAR-21-330	The NCI encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from participants in the PLCO screened arm, and a one-time collection of buccal cells from participants in both arms. Tissue microarrays (TMA) of formalin-fixed, paraffin-embedded (FFPE) tumor tissues are also available for a subset of the cases for selected cancers. This FOA supports a wide range of research including biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers.	Letter of intent due: 1/11/22 5/10/22 9/11/22 Proposal due: 2/11/22 6/10/22 10/11/22	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-330.html
27.	Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional/R21 Clinical Trial Not Allowed) (NIH/NCI)	PAR-21-331 (R01) PAR-21-332 (R21)	Through these FOAs, NCI invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter-term outcomes such as weight loss and diabetes. PAR-21-331 is geared for investigators who have generated unpublished preliminary data; PAR-21-332 supports proof of concept studies for feasibility and exploratory development.	Letter of intent due: 10/12/21 1/5/22 5/5/22 Proposal due: 11/12/21 2/5/22 6/5/22 |(R01) Letter of intent due: 10/18/21 1/16/22 5/16/22 Proposal due: 11/18/21 2/16/22 6/16/22 (R21)	Up to $500,000 per year, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	https://grants.nih.gov/grants/guide/pa-files/PAR-21-331.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-21-332.html (R21)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			CANCER			
28.	Translational and Basic Science Research in Early Lesions Research and Coordinating Centers (TBEL) (U54/U24 Clinical Trial Not Allowed) (NIH/NCI)	RFA-CA-21-054 (U54) RFA-CA-21-055 (U24)	RFA-CA-21-054 solicits U54 applications for the establishment of Research Centers, one of the two units of the Translational and Basic Science Research in Early Lesions (TBEL) program. RFA-CA-21-055 solicits U24 applications for the establishment of the Coordinating and Data Management Center (CDMC). The ultimate goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and facilitate biology-backed precision prevention approaches.	Letter of intent due: 10/2/21 Proposal due: 11/2/21	Up to $1 million, for up to 5 years (U54) Up to $500,000, for up to 5 years (U24)	https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-054.html (U54) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-055.html (U24)
29.	DOD Melanoma, Discovery Award (DoD/ USAMRAA)	W81XWH-21-MRP-DA	The FY21 MRP Discovery Award supports innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications in melanoma research. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation regarding an important question for melanoma research and/or patient community. The proposed research project should include a well-formulated, testable hypothesis based on a sound scientific rationale and study design. Preliminary data are not required. If preliminary data is presented it will be evaluated for its support of the specific aims, objectives, and/or hypothesis.	Pre-application due: 10/20/21 Proposal due: 11/10/21	Up to $200,000, for up to 2 years	https://cdmrp.army.mil/funding/mrp
			CANNABIS RESEARCH (2)			
30.	Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R01/R21 - Clinical Trial Optional) (NIH/NIDA)	RFA-DA-22-028 (R01) RFA-DA-22-039 (R21)	These FOAs support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of varying concentrations of Δ9-tetrahydrocannabinol (THC) that are present in cannabis and cannabis products, using various routes of administration.	Letter of intent due: 1/9/22 Proposal due: 2/9/22	Up to $500,000 per year, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-028.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-039.html (R21)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			CARDIOVASCULAR HEALTH (8)			
31.	NOSI: Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood (NIH/NHLBI)	NOT-HL-21-015 NOT-HL-21-020	There are eight grants within these notices. The NHLBI is highlighting its interest in research to promote cardiovascular and cardiometabolic health in early stages of the lifecourse. NHLBI encourages the submission of applications unique to: 1) understanding the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases from pre-adolescence into adolescence and adolescence into young adulthood, and 2) developing precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases.	Multiple deadlines; first available due date: 10/5/21	Dependent on award and award mechanism	https://grants.nih.gov/grants/guide/notice-files/NOT-HL-21-015.html https://grants.nih.gov/grants/guide/notice-files/NOT-HL-21-020.html
			CENTRAL NERVOUS SYSTEM (3)			
32.	Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional), Incubator Hubs (U54 Clinical Trial Not Allowed), and MedTech Translator (UG3/UH3 - Clinical Trial Optional) (NIH)	PAR-21-282 (U44) PAR-21-314 (U54) PAR-21-315 (UG3/UH3)	PAR-21-282 and PAR-21-315 support SBCs in pursuing translational activities and clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported by this FOA include implementation of clinical prototype devices, non-clinical safety and effectiveness testing, design verification and validation activities. PAR-21-314 supports incubator hubs to help innovators build medical devices as close to the 'final system' as possible.	Letter of intent due: 9/20/21 1/18/22 |5/20/22 Proposal due: 10/20/21 2/18/22 6/20/22	Dependent upon proposal and award type; for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-282.html (U44) https://grants.nih.gov/grants/guide/pa-files/PAR-21-314.html (U54) https://grants.nih.gov/grants/guide/pa-files/PAR-21-315.html (UG3/UH3)
			CHILD DEVELOPMENT (2)			
33.	Learning Disabilities Innovation Hubs (P20 Clinical Trial Optional) (NIH/NICHD)	RFA-HD-22-005	This FOA invites exploratory grant applications, hereafter referred to as the Learning Disabilities Innovation Hubs or LD Hubs, addressing the etiology, manifestation, prevention and remediation of reading, writing and/or mathematics specific learning disorders (SLDs). An LD Hub includes a single research project and a Leadership Core that support the goals and aims of the LD Hub.	Letter of intent due: 10/30/21 Proposal due: 11/30/21	Up to $390,000 per year, for up to 4 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-005.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			CHILD DEVELOPMENT			
34.	Impact of Technology and Digital Media (TDM) Exposure/Usage on Child and Adolescent Development (P01 Clinical Trial Optional) (NIH/NICHD)	RFA-HD-22-009	This FOA invites submission of P01 applications to support integrated, multi-project research programs to create a locus of research examining the pathways by which TDM exposure and usage impact developmental trajectories and health outcomes in early childhood (ages birth-8) or adolescence (ages 9-17).	Letter of intent due: 10/29/21 Proposal due: 11/29/21	Up to $1 million per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-22-009.html
			CHRONIC PAIN (2)			
35.	Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed) (NIH)	PA-18-939	This FOA encourages epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions.	Proposal due: 10/16/21 2/16/22 6/16/22	Up to $275,000, for up to 2 years	https://grants.nih.gov/grants/guide/pa-files/pa-18-939.html
36.	HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional) (NIH)	RFA-NS-22-016	Applications are being solicited from interdisciplinary teams to utilize multi-faceted approaches to discovering the mechanisms of device-based pain relief for FDA-approved or -cleared therapies. Device technologies within scope of this FOA only include medical devices for pain that have already received FDA Premarket Approval (PMA) or FDA Premarket Notification 510(k). Devices that are exempt from Premarket Notification 510(k) are not within scope of this FOA. Projects should also propose/investigate methods for implementing new or optimized therapeutic procedures that have a high likelihood of improving the standard of care.	Letter of intent due: 10/3/21 Proposal due: 11/3/21	Up to $1,500,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-016.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			CORONAVIRUS (6)			
37.	NOSI: Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations (NIH)	NOT-MH-21-330	There are six opportunities listed within this NOSI. This NOSI highlights interest in research to strengthen the understanding and response to the COVID-19 pandemic and help us prepare more effectively for future public health emergencies. The purpose of this Notice is to 1) emphasize the roles and impacts of interventions, particularly those under the umbrella of digital health, as well as community-engaged and multi-level interventions in healthcare settings to address access, reach, delivery, engagement, effectiveness, scalability, and sustainability of services that are utilized during and following the pandemic, and 2) encourage the leveraging of existing large-scale data sources with broad population coverage to improve prediction of various mitigation efforts on transmission reduction and on social and economic impacts, and assess the downstream health and healthcare access effects, with an emphasis on underserved and vulnerable populations. Additionally, the use of large-scale data sources to study the indirect health impacts of the pandemic and subsequent social and economic changes is needed to understand the costs and benefits of various COVID-19 mitigation strategies.	Multiple deadlines; first available due date: 10/5/21	Dependent on proposal and award, for up to 5 years	https://grants.nih.gov/grants/guide/notice-files/NOT-MH-21-330.html
			DARPA (3)			
38.	Biological Technologies BAA (DoD/DARPA)	HR001121S0025	BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, and deep exploration of changing ecologies and environments for improving U.S. capabilities and resilience. BTO's programs operate across a wide range of scales, from individual cells to the warfighter to global ecosystems. BTO responds to the urgent and long-term needs of the DoD and addresses national security priorities. BTO is interested in submissions related to the following topic areas: Human Performance, Materials, Sensors, Processing, Biosecurity, Biodefense	Abstracts & proposals accepted on a rolling basis until 4/22/22	Dependent upon proposal	https://sam.gov/opp/dfe93a5637fc419a8ea392ee949f9c79/view

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			DARPA			
39.	Redefining Possible (DoD/DARPA)	HR001121 S0029	The Tactical Technology Office (TTO) of the Defense Advanced Research Projects Agency (DARPA) is soliciting executive summaries, proposal abstracts, and proposals for applied research, advanced technology development, platform demonstrations, or systems studies that aim to redefine the future of warfighting across four domains: Air, Ground, Maritime, and Space. The mission of the Tactical Technology Office (TTO) is to redefine access and delivery of effects to every domain in the battlespace: space, air, ground, sea, and undersea in support of national security policy. This includes both platforms as well as the enabling support elements for delivering effects, such as unit-level autonomy or human-machine collaboration. TTO accomplishes this mission by placing bold bets on developing new and novel system technologies and conducting platform demonstrations in realistic, operationally relevant conditions to support technology transition.	Proposals accepted on a rolling basis until 6/10/22	Up to $1 million, for up to 18 months	https://www.grants.gov/web/grants/view-opportunity.html?oppId=334117 (Full Announcement in Related Documents Tab)
40.	Defense Sciences Office, Office-wide (DoD/DARPA)	HR001121 S0032	The mission of the DARPA Defense Sciences Office (DSO) is to identify and create the next generation of scientific discovery by pursuing high-risk, high-payoff research initiatives across a broad spectrum of science and engineering disciplines and transforming these initiatives into disruptive technologies for U.S. national security. In support of this mission, the DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: (1) Frontiers in Math, Computation and Design, (2) Limits of Sensing and Sensors, (3) Complex Social Systems, and (4) Anticipating Surprise. Each of these thrust areas is described below and includes a list of example research topics that highlight several (but not all) potential areas of interest. Proposals must investigate innovative approaches that enable revolutionary advances.	Abstracts accepted on a rolling basis until 6/10/22	Dependent upon proposal	https://sam.gov/opp/f08ce40db929467ab7a8cdac02345b70/view (Full Announcement in Related Documents Tab)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			DENTAL & CRANIOFACIAL RESEARCH (3)			
41.	NOSI: Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42, R43/R44 Clinical Trial Not Allowed) (NIH/NIDCR)	NOT-DE-21-012	There are two grants within this NOSI. This NOSI invites applications that propose development and implementation of novel digital dentistry methods by integrating different imaging modalities (e.g., CBCT, MRI, ultrasound, optical) with advanced image processing algorithms and expert systems to assist in oral health assessment, pre-surgical planning and surgical guidance. Development of advanced image processing software, including artificial intelligence (AI) tools, for image detection, classification, interpretation and clinical decision making in dental radiology are highly encouraged. Performance of new imaging-based systems must be verified and validated according to sensitivity, specificity, and accuracy requirements in support of specific intended preclinical and clinical utilities.	Multiple deadlines; first available due date: 1/5/22	Phase I: Up to $259,613, for up to 2 years Phase II: Up to $1.7 million, for up to 3 years	https://grants.nih.gov/grants/guide/notice-files/NOT-DE-21-012.html
42.	NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) (NIH/NIDCR)	PAR-21-317	This FOA encourages UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials related to dental, oral, or craniofacial conditions. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase (UH3) of up to five years.	Letter of intent due: 1/8/22 5/7/22 9/4/22 Proposal due: 2/8/22 6/7/22 10/4/22	Dependent upon proposal and award mechanism	https://grants.nih.gov/grants/guide/pa-files/PAR-21-317.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			DIABETES (2)			
43.	High-Resolution Exploration of the Human Islet Tissue Environment [HIRN Human Pancreas Analysis Consortium (HPAC)] (U01 - Clinical Trial Not Allowed) (NIH/NIDDK)	RFA-DK-21-017	This initiative will support the in-depth description of structural and functional components of the human pancreatic tissue architecture and their contribution to islet tissue homeostasis and function. This initiative will also support the development and use of innovative functional assays in live human pancreatic cells or tissues for the manipulation or visualization of regulatory processes that control specific aspects of islet function and dysfunction. Projects in response to this initiative are encouraged to explore the contribution of specific cell subtypes or regulatory pathways to human T1D pathogenesis, and to develop molecular tools to manipulate components of the islet tissue environment as a first step towards the development of novel regenerative or therapeutic strategies.	Letter of intent due: 2/3/22 Proposal due: 3/3/22	Up to $600,000 per year, for up to 4 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-017.html
44.	National Program for the Career Development Of Physician Scientists in Diabetes Research (Diabetes - Docs) (K12 Clinical Trial Optional) (NIH/NIDDK)	RFA-DK-21-019	This FOA encourages applications from organizations that propose creative and innovative institutional research career development programs in the mission area(s) of the NIH. The NIDDK seeks to create a single highly collaborative national program, which will provide support for physician-scientist Scholars in diabetes research across the country. While the majority of the career development funding will be for type 1 diabetes research, the opportunity includes an expansion for research in type 2 diabetes.	Proposal due: 11/18/21	Up to $1.3 million per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-019.html
			DIGESTIVE DISEASES (2)			
45.	NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01 Clinical Trial Optional) (NIH/NIDDK)	RFA-DK-21-022	This FOA invites applications to renew the NIDDK IBDGC to address three main research objectives: 1) to further characterize the genetic architecture of IBD phenotypes within populations currently underrepresented in IBD genomic research, integrating genetic and environmental predictors in risk models; 2) to identify the causal genetic variants and the genes, proteins and pathways they act upon within susceptibility loci for IBD phenotypes; and 3) to elucidate the biological mechanisms by which risk-associated and protective variants influence the pathophysiology of IBD and its clinically important sub-phenotypes and outcomes. The long-range goal of the research to be carried out by the IBDGC is the enhancement of our understanding of the pathophysiologic mechanisms of IBD in order to improve patient outcomes.	Letter of intent due: 11/21/21 Proposal due: 12/21/21	Up to $375,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-022.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			DIGESTIVE DISEASES			
46.	Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional) (NIH/NIDDK)	RFA-DK-21-026	The objective of the Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs) is to bring together, on a cooperative basis, basic and clinical investigators to enhance the effectiveness of their research related to digestive and/or liver diseases and their complications. DDRCCs are meant to improve communication among investigators and to integrate, coordinate, and foster interdisciplinary research involving the etiology, treatment, and prevention of digestive and/or liver diseases.	Letter of intent due: 1/17/22 5/8/23 Proposal due: 2/17/22 6/8/23	Up to $750,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-026.html
			DIVERSITY & INCLUSION (4)			
47.	Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00; Trials Vary) (NIH)	PAR-21-271 PAR-21-272 PAR-21-273	The MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers.	Letter of intent due: 9/27/21 1/12/22 5/12/22 Proposal due: 10/27/21 2/12/22 6/12/22	Up to $249,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/par-21-271.html https://grants.nih.gov/grants/guide/pa-files/PAR-21-272.html https://grants.nih.gov/grants/guide/pa-files/PAR-21-273.html
48.	Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional) (NIH)	PAR-21-313	This FOA is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the NIDDK or NHGRI. New investigators at the time of award under this FOA will have had less than $125,000 direct costs of combined research funding. This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence.	Proposal due: 10/16/21 2/16/22 6/16/22	Up to $125,000, for up to 3 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-313.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			ENVIRONMENTAL HEALTH (2)			
49.	Innovative Approaches for Improving Environmental Health Literacy (R43/R44 and R41/R42 Clinical Trial Not Allowed) (NIH/NIEHS)	RFA-ES-21-008 (R43/R44) RFA-ES-21-009 (R41/R42)	These FOAs solicit Phase I (R41/R43), Phase II (R42/R44), and Fast-track (R42) STTR grant applications from SBCs in collaboration with environmental science researchers to develop novel tools, activities, or materials to build environmental health literacy for a variety of groups, including community members, health care and public health professionals, educators, and students of all ages. As part of its Partnerships for Environmental Public Health (PEPH) Program, NIEHS is interested in developing tools that build capacity, improve environmental health literacy, and support citizen science endeavors. In addition, there is a need for improved approaches for communicating Environmental Health Science concepts for diverse audiences, including K-12 education, undergraduate and graduate education, and information for health care professionals. These approaches or resources should be fit-for-purpose to meet the needs of the following audiences: community members, health care and public health professionals, educators, and students of all ages.	Letter of intent due: 10/10/21 Proposal due: 11/11/21	Phase I: Up to $259,613, for up to 1 year Phase II: Up to $1,730,751, for up to 2 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-21-008.html (R43/R44) http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-21-009.html (R41/R42)
			FETAL ALCOHOL SYNDROME (1)			
50.	Pre-Announcement: I-FASD: Understanding Clinical Data and Pathways through Care to Inform Surveillance of Children with FASDs (CDC/NCBDDD)	CDC-RFA-DD22-2202	Surveillance of children with Fetal Alcohol Spectrum Disorders is essential for understanding the magnitude of these conditions in the population, as well as understanding the associated needs, healthcare utilization, and comorbidities. Information from existing electronic health record data systems are a potential source of surveillance data, but a better understanding of these data and associated quality are needed.	Estimated post date: 7/1/22 Estimated proposal due: 8/30/22	Up to $450,000	https://www.grants.gov/web/grants/view-opportunity.html?oppId=335567

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			GENOMICS (4)			
51.	NOSI: Genomics Education Interactive Digital Media Resources (SBIR/STTR) (NIH/NHGRI)	NOT-HG-21-038	There are two grants within this notice. The research objective of this NOSI is the development of new educational products that will advance our understanding of how interactive digital media gaming can improve education in genomics. It is anticipated that increasing high school, college, advanced degree students and professionals' achievement in genomic fields through IDM resources will encourage them to better understand genomics. Work that is not genomics-focused or focused on a different target population is outside of the domain of this NOSI.	Proposal due: 1/5/22 4/5/22 9/5/22	Phase I: Up to $259,613, for up to 1 year Phase II: Up to $1,730,751, for up to 2 years	https://grants.nih.gov/grants/guide/notice-files/NOT-HG-21-038.html
52.	Limited Competition: Knockout Mouse Production and Phenotyping Project and Data Coordination Center and Database (UM1) Clinical Trial Not Allowed (NIH)	RFA-HG-21-036 RFA-HG-21-037	RFA-HG-21-036 supports work to design and produce null-mutant mice and phenotype them. It is expected that centers will employ optimized CRISPR protocols for efficient production of null alleles in zygotes as part of a high-throughput pipeline. Targets will be selected from the remaining set of 1:1 human-mouse ortholog genes that do not have associated phenotype information. RFA-HG-21-037 supports a Data Coordination Center and Database (DCCDB) to perform the validation, analysis, annotation, visualization, and dissemination of the phenotype data from the knockout lines.	Proposal due: 11/1/21	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-036.html https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-037.html
			GLOBAL HEALTH (1)			
53.	The USAID Global Health Broad Agency Announcement for Research and Development (2018) (USAID)	GLOBALHEALTH-BAA-2018	This FOA seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address the most pressing problems in global health. The United States Agency for International Development (USAID) invites organizations and companies to participate with USAID, in cooperation with its partners, to generate novel tools and approaches that accelerate and sustain improved health outcomes in developing countries.	Expression of interest accepted on a rolling basis though 5/30/22	Dependent upon proposal and award type	https://www.grants.gov/web/grants/view-opportunity.html?oppId=305999 (Full Announcement in Related Documents Tab)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			HEALTHCARE DISPARITIES (4)			
54.	Pre-Announcement: NIH Health Care Systems Research Collaboratory - Pragmatic and Implementation Trials of Embedded Interventions and Coordinating Center (UG3/UH3 Clinical Trials Optional/U24 Clinical Trial Not Allowed) (NIH)	NOT-AT-21-015	The NCCIH, and other NIH ICOs, intends to publish a FOA to solicit applications for phased cooperative research applications to conduct efficient, large-scale embedded pragmatic or implementation trials within health care systems, as well as a FOA to support a Coordinating Center. Research focused on improving health outcomes in Americans across the lifespan and addressing health disparities in populations who experience higher rates of certain diseases and higher mortality compared with the general population will be a high priority. Results from the pragmatic or implementation trials supported by this FOA should inform policy makers, payers, health care providers and patients across diverse patient care settings.	Estimated post date: 9/15/21 Estimated proposal due date: 11/15/21	Up to $500,000, for one year (UG3) Up to $1 million per year, for up to 4 years (UH3) Up to $3 million per year (U24)	https://grants.nih.gov/grants/guide/notice-files/NOT-AT-21-015.html (UG3/UH3) https://grants.nih.gov/grants/guide/notice-files/NOT-AT-21-016.html (U24)
55.	Pre-Announcement: Strategies to Implement Evidence-based Care to Reduce High Burden Racial and Ethnic Disparities (AHRQ)	NOT-HS-21-019	AHRQ intends to publish a NOFO to disseminate and implement patient-centered outcomes research findings that have been found to be the most impactful in reducing specific healthcare disparities. Interventions must be focused specifically on the goal of reducing disparities by wide-scale implementation of evidence-based care. Grant applicants may propose interventions in different healthcare settings (e.g., primary care, long-term care) based on where the comparative effectiveness evidence work was conducted. Though not limited to the following, some areas where comparative effectiveness interventions have evidence for decreasing disparities include promoting improved cancer and chronic condition screening, improving control of chronic conditions, and improving prenatal care, maternal health, and infant mortality.	TBA	TBA	https://grants.nih.gov/grants/guide/notice-files/NOT-HS-21-019.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			HEALTHCARE DISPARITIES			
56.	A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT; U01 Clinical Trial Not Allowed) (NIH/NCI)	RFA-CA-21-057 (U01) RFA-CA-21-058 (U24)	The NCI is soliciting applications for a CUSP2CT U01 site and a CUSP2CT U24 Data, Evaluation and Coordinating Center (DECC). CUSP2CT is a program designed to increase referral to NCI-supported clinical trials (CTs) among underrepresented racial/ethnic (R/E) minority populations who experience disproportionately higher rates of incidence, morbidity, and mortality for numerous cancer types in comparison to Non-Hispanic Whites (NHW).	Letter of intent due: 10/19/21 Proposal due: 11/19/21	Up to $450,000 per year, for up to 5 years (U01) Up to $350,000, for up to 5 years (U24)	https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-057.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-057.html (U24)
			HEMOPHILIA (1)			
57.	An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immunogenicity in Severe Hemophilia A: Hemophilia A Analytical Cohort Research Program (UG3/UH3 Clinical Trial Not Allowed) (NIH/NHLBI)	RFA-HL-22-004	This FOA seeks applications that propose the establishment of a Hemophilia A Analytical Cohort Research Program (HARP) that will: 1) collaborate with an established consortium of clinical centers to support the recruitment, enrollment, and follow-up of an antenatal/neonatal/ pediatric cohort in severe hemophilia A; 2) provide data management, laboratory, and biospecimen support necessary for the establishment of a unique and sharable biospecimen resource annotated with robust intergenerational clinical and demographic data to enable future studies of FVIII immunogenicity; and 3) develop and implement protocols and procedures to conduct hypothesis-driven research studies utilizing data and biospecimens from the antenatal/neonatal/pediatric cohort.	Letter of intent due: 9/19/21 Proposal due: 10/19/21	Dependent upon proposal, for up to 7 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-004.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			HIV/AIDS (15)			
58.	Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program (ADAP) Training and Technical Assistance (HHS/HRSA)	HRSA-22-025	This funding is to build the capacity of ADAPs through tools and technical assistance to maximize the impact of ADAPs in improving the health outcomes of people with HIV in a changing health care environment. In collaboration with HRSA, the funded entity will provide technical assistance to RWHAP Part B recipients to strengthen ADAP administrative structures and operations, and to strengthen the capacity of ADAPs to implement and administer medication assistance and health insurance assistance programs to optimize client health outcomes. The funded entity will also be responsible for conducting an ongoing assessment of RWHAP Part B recipients' technical assistance needs related to ADAP and adapting technical assistance to changing needs.	Proposal due: 11/22/21	Up to $500,000 per year, for up to 5 years	https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=f73a8c42-6799-424b-9c5d-f97fbdf991c3
59.	Pre-Announcement: Coordinating Center/Research Bases/Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (U24/UG1 Clinical Trial Required) (NIH/NCI)	NOT-CA-21-112 (U24) NOT-CA-21-113 (UG1) NOT-CA-21-114 (UG1)	The 'CASCADE' Network seeks to conduct pragmatic clinical trials evaluating the effectiveness of clinically proven interventions to overcome barriers and reduce failures in the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. The UG1 Research Bases will provide scientific and statistical leadership for developing and analyzing multi-institutional clinical trial concepts and protocols for implementation at multiple UG1 Clinical Sites, and partner with the U24 Coordinating Center and the UG1 Clinical Sites.	Estimated post date: 10/15/21 Estimated proposal due date: 12/28/21	Up to $750,000 per year, for up to 5 years. (U24) Up to $400,000 per year, for up to 5 years. (UG1)	https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-112.html (U24) https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-113.html (UG1) https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-114.html (UG1)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			HIV/AIDS			
60.	Pre-Announcement: Adolescent Medicine Trials Network for HIV/AIDS Intervention Centers (UM1/UM2 Clinical Trial) (NIH/NICHD)	NOT-HD-21-043	The NICHD intends to solicit applications for a research program cooperative agreement to support the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) to develop and conduct innovative behavioral, community-based, translational, therapeutic, microbicide and vaccine trials in youth ages 13-24 years at-risk for HIV and living with HIV, with a focus on the inclusion of minors. A Scientific Leadership Center (UM2 Clinical Trial Required), and Operations and Collaborations Center (UM1 Clinical Trial) will be created.	Estimated post date: 10/29/21 Estimated proposal due date: 1/7/22	TBD	https://grants.nih.gov/grants/guide/notice-files/NOT-HD-21-043.html
61.	Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 and R41/42 Clinical Trial Not Allowed) (NIH/NICHD/NIMH)	PAR-21-297 (R43/R44) PAR-21-298 (R41/R42)	These FOAs support the development of new and innovative long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy in adolescent and young women. Applications for MPT development may involve pharmacokinetic, pharmacodynamic, safety, and drug-drug interactions studies. It also encourages biobehavioral and behavioral/social studies to identify MPT end user preferences factors and other behavioral/social factors that could promote increased MPT use in adolescent and young women.	Letter of intent due: 11/9/21 11/9/22 11/9/23 Proposal due: 12/9/21 12/9/22 12/9/23	Dependent upon proposal and award mechanism	https://grants.nih.gov/grants/guide/pa-files/PAR-21-297.html (R43/R44) https://grants.nih.gov/grants/guide/pa-files/PAR-21-298.html (R41/R42)
62.	HIV Prevention and Alcohol (R01/R34 Clinical Trials Optional) (NIH)	RFA-AA-21-016 (R01) RFA-AA-21-017 (R34)	These FOAs seek to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research.	Letter of intent due: 11/16/21 Proposal due: 12/16/21	Up to $500,000, for up to 5 years (R01) Up to $450,000, for up to 3 years (R34)	https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-016.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-017.html (R034)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			HIV/AIDS			
63.	American Women: Assessing Risk Epidemiologically (AWARE) (R01 Clinical Trial Optional) (NIH)	RFA-AI-21-058	This FOA will support research that combines epidemiologic methods, digital technology, and data science approaches to better understand HIV prevention, transmission, and early care-cascade points for women living in the US. Applications must: 1) determine the best ways to identify, enroll, and retain cohorts of women living in the US who are behaviorally vulnerable to HIV; and 2) develop a knowledgebase comprised of cohort data from women augmented with other data sources including big data sources. Findings should not only lead to a better understanding of how women remain vulnerable to HIV but also inform future pilot interventions aimed at decreasing the incidence of HIV and other STIs among cisgender, transgender, and gender non-conforming women.	Letter of intent due: 11/9/21 Proposal due: 12/9/21	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-058.html
64.	High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) (NIH/NIDA)	RFA-DA-22-040	This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). This FOA is designed to attract exceptionally talented investigators to conduct innovative, potentially groundbreaking investigations at the intersection of HIV and substance use.	Letter of intent due: 1/15/22 7/15/22 1/15/23 Proposal due: 2/15/22 8/15/22 2/15/23	Dependent on proposal, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-040.html
65.	Innovative Multi-Level Approaches & Strategies to Prevent, Test and Treat HIV in Primary Care Settings in Health Disparity Populations in Geographic Hot Spots in the U.S (NIH/NIMH)	RFA-MD-22-001	This initiative will support intervention research that tests innovative approaches and strategies to prevent, test and treat HIV among health disparity populations or subpopulations within primary care settings located in geographic areas with a high rate of new infections. Trials should include measurement of individual-level clinical or behavioral outcomes such as HIV viral load and being tested for HIV. Am R01 - Clinical Trial is Required	Letter of intent due: 12/14/21 Proposal due: 1/14/22	Up to $500,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-22-001.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			HIV/AIDS			
66.	Deciphering Immune-CNS interactions in people living with HIV on Anti-Retroviral therapy (R01 Clinical Trial Optional); in HIV utilizing in-vitro and in-vivo model systems (R21 Clinical Trial Not Allowed) (NIH/NIMH/ NINDS)	RFA-MH-21-250 (R01) RFA-MH-21-251 (R21)	RFA-MH-21-250 supports studies to better comprehend the mechanisms contributing to the CNS co-morbidities in people living with HIV on Anti-Retroviral therapy by deciphering the Immune-Central Nervous System (CNS) interactions. Applications testing a fully conceptualized and hypothesis-based premise founded on adequate preliminary data are appropriate for this R01; applicants pursuing exploratory and high-risk research projects should submit to the R21 announcement, RFA-MH-21-251. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.	Letter of intent due: 11/7/21 Proposal due: 12/7/21	Dependent on Proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-250.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-251.html (R21)
			IMMUNOLOGY & INFECTIOUS DISEASE (5)			
67.	Pre-Announcement: Strengthening Collaboration Between TB Control Programs and Affiliated Partners in the United States (CDC/ NCHHSTP)	CDC-RFA-PS22-2205	The recipient will build on strengthening collaborations between TB control programs and their affiliated partners in the United States, to identify and forge collaborations that will accelerate TB elimination. The recipient will enhance communication, collaboration, consultation and conduct professional development for TB controllers, other stakeholders and key partners in the United States.	Estimated post date: 4/5/22 Estimated proposal due date: 6/4/22	Up to $320,042	https://www.grants.gov/web/grants/view-opportunity.html?oppId=335353

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			IMMUNOLOGY & INFECTIOUS DISEASE			
68.	Pre-Announcement: Strengthening Civil Surgeons' Capacity to Improve LTBI Surveillance and Outcomes Among Status Adjusters (CDC/ NCHHSTP)	CDC-RFA-PS22-2207	The CDC and NCHHSTP anticipates FY 2022 cooperative agreement funds for a pilot project that will improve public health surveillance of latent TB infection (LTBI) among noncitizens residing in the United States on temporary visas who are applying for legal permanent residency and improve their linkage to LTBI care and treatment through health departments' collaboration with Civil Surgeons.	Estimated post date: 4/7/22 Estimated proposal due date: 6/6/22	Up to $533,000, per award	https://www.grants.gov/web/grants/view-opportunity.html?oppId=335352
69.	Pre-Announcement: Strengthening Harm Reduction Programs for People Who Use Drugs (CDC/ NCHHSTP)	CDC-RFA-PS22-2208	This four-year program will strengthen the capacity and improve the performance of harm reduction programs throughout the United States. The purpose of this project is to strengthen harm reduction programs' ability to serve people who use drugs and engage in measurement and surveillance. It is comprised of three components: providing technical assistance, using data to assess and improve the utilization of services, and enhancing implementation of services for people who use drugs. Activities will include providing technical assistance to harm reduction programs, harm reduction program monitoring and evaluation, building and sustaining a supportive network for harm reduction programs, and service integration for people who use drugs.	Estimated post date: 2/1/22 Estimated proposal due date: 5/1/22	TBA	https://www.grants.gov/web/grants/view-opportunity.html?oppId=335371
70.	Ecology and Evolution of Infectious Diseases (NSF/NIH)	NSF 21-609	The multi-agency EEID program supports research on the ecological, evolutionary, organismal, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease (re)emergence and transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of (re)emergence and transmission among any host species, including but not limited to humans, non-human animals, and/or plants.	Proposal due: 11/24/21 11/16/22 11/17/23	Up to $3 million, for up to 5 years	https://www.nsf.gov/pubs/2021/nsf21609/nsf21609.htm

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			IMMUNOLOGY & INFECTIOUS DISEASE			
71.	Emerging Infections Sentinel Networks (EISN) Research (CDC/ERA)	RFA-CK-22-003	The purpose of this NOFO is to provide a funding mechanism for EISN research activities, specifically within a network of emergency departments (EDs). The EISN program will assist in operating emergency department provider-based sentinel networks. These networks will contribute to surveillance for emerging infectious diseases (EID), such as those caused by agents of bioterrorism, pathogens of pandemic potential, drug-resistant, foodborne or waterborne microorganisms, and vaccine-preventable or potentially vaccine-preventable diseases, and help inform operational public health and healthcare decisions during public health emergencies, help better understand and address the disproportionate impact of EIDs on underserved and disadvantaged populations, and enhance information exchange.	Letter of intent due: 9/17/21 Proposal due: 11/1/21	Up to $300,000 per award	https://www.grants.gov/web/grants/view-opportunity.html?oppId=334472 (Full Announcement in Related Documents Tab)
			MEDICAL COUNTERMEASURES (1)			
72.	Reimagining Protein Manufacturing (RPM) (DoD/DARPA)	HR001121S0038	The RPM program aims to ensure timely DoD access to critical medical countermeasures (MCMs) by establishing the foundational technologies needed for fully distributed, on-demand manufacturing of protein-based MCMs and associated raw materials. To achieve this goal, RPM will develop technologies to enable immediate synthesis of bioactive protein MCMs and raw material production enzymes at a yield corresponding to > 500 doses per week. This technology will allow the DoD to rapidly secure access to both therapeutic proteins and enzymes needed for nucleic acid-based MCM synthesis, and reduce reliance on complex supply chains.	Abstract due: 9/23/21 Proposal due: 11/16/21	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=335391 (Full Announcement in Related Documents Tab)
			MENTAL HEALTH (1)			
73.	Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed) (NIH/NIMH)	PAR-21-316	This FOA encourages innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. Proposed research should seek to: Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future service delivery intervention development; Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; Integrate and analyze large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic approaches.	Letter of intent due: 1/5/22 5/5/22 9/5/22 Proposal due: 2/5/22 6/5/22 10/5/22	Dependent on proposal, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-316.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			MIGRAINE (1)			
74.	Comparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention – Cycle 3 2021 (PCORI)	N/A	PCORI seeks to fund rigorous, large-scale pragmatic trials that compare newly available pharmacologic and/or evidence-based nonpharmacologic treatments for the prevention of migraine. Applications should respond to the following question: What is the comparative effectiveness of novel pharmacologic and/or evidence-based nonpharmacologic treatments for the prevention of migraine? PCORI is particularly interested in studies that compare emerging pharmacological options such as CGRP antagonists to standard prophylactic therapy or to each other. PCORI is also interested in studies that examine the comparative effectiveness of evidence-based nonpharmacological options for migraine prevention.	Letter of intent due: 10/5/21 Proposal due: 1/11/22	Up to $10 million, for up to 5 years	https://www.pcori.org/funding-opportunities/announcement/pharmacologic-nonpharmacologic-treatments-migraine-prevention-cycle-3-2021
			MISSILE DEFENSE AGENCY (1)			
75.	Missile Defense Agency (MDA) Innovation, Science & Technology (IS&T) Broad Agency Announcement (BAA) FAR and Non-FAR Solutions (DoD/MDA)	HQ0860-21-S-0001	White papers are sought for cutting-edge innovative research that could enable new, improved, and disruptive missile defense technologies; improved speed and/or lowered cost of producing critical defense components; and yield increased operational capabilities. MDA/DV is interested in specific research areas but applicants are not limited to these topics. Topics include RF and IR sensors and communications, materials and processing, artificial intelligence, and cybersecurity. For a full list of applicable research topics, see full solicitation.	White papers accepted on a rolling basis through 4/2/23	Dependent upon proposal, for up to 3 years	https://sam.gov/opp/70b8d45310ca44fba9df6e5eaed4d5a2/view
			NATIONAL VIRTUAL BIOTECHNOLOGY LABORATORY (1)			
76.	Opportunities from the National Virtual Biotechnology Laboratory (NVBL) (DOE)	N/A	NVBL is a consortium of National laboratories, taking advantage of DOE user facilities, including light and neutron sources, nanoscale science centers, sequencing and bio-characterization facilities, and high-performance computer facilities, to address key challenges in responding to the COVID-19 threat. Examples include developing innovations in testing capabilities, identifying targets for medical therapeutics, providing epidemiological and logistical support, and addressing supply chain bottlenecks.	N/A	Dependent upon solicitation and proposal	https://science.osti.gov/nvbl

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			NEPHROLOGY (1)			
77.	Pediatric Centers of Excellence in Nephrology (PCEN) (P50 Clinical Trial Optional) (NIH/NIDDK)	RFA-DK-21-024	This FOA invites applications for the PCEN to support basic, translational and clinical research in pediatric kidney disease. The goals of this program are: 1. to attract new scientific expertise to the study of human pediatric renal physiology, kidney development, and pediatric kidney disorders; 2. to encourage multidisciplinary research in these areas; and 3. to develop the pediatric nephrology research community through a national research symposium, broad sharing of research resources, and a national Pilot and Feasibility grant program.	Letter of intent due: 10/18/21 Proposal due: 11/18/21	Up to $625,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-024.html
			NEUROFIBROMATOSIS (1)			
78.	DOD Neurofibromatosis Clinical Trial Consortium Award (DoD/ USAMRAA)	W81XWH-21-NFRP-CTCA	The FY21 NFRP Clinical Trial Consortium Award is intended to support a major goal/productdriven consortium of exceptional institutions and investigators that will accelerate the clinical translation of basic NF research and ultimately decrease the impact of the disease. The objectives of the rOTA are the conception, design, development, and conduct of collaborative Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis.	Pre-application due: 9/17/21 Proposal due: 10/29/21 (Invitation only)	Up to $25 million, for up to 10 years	https://www.grants.gov/web/grants/view-opportunity.html?oppId=335360 (Full Announcement in Related Document Tab)
			OBESITY (1)			
79.	Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed) (NIH) (NIH)	PAR-21-305	This FOA is intended to encourage and support research in which a unique and time sensitive opportunity has arisen to collect baseline data and then prospectively assess effectiveness of an imminent policy or program that is likely to prevent or reduce obesity in a given population. Applications submitted to this FOA should demonstrate that measures collected and evaluated will allow for meaningful and scientifically valid conclusions to be made about the effects of the policy or program on the target behaviors and/or weight.	Proposal due: 9/22/21 10/14/21 11/9/21	Dependent upon proposal, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-305.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			OFFICE OF NAVAL RESEARCH (3)			
80.	FY21 Long Range Broad Agency Announcement (BAA) for Navy and Marine Corps Science and Technology (Dod/Navy)	N00014-21-S-B001	The Office of Naval Research (ONR), ONR Global, and Marine Corps Warfighting Lab (MCWL) are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. Readers should note that this is an announcement to declare ONR, ONRG and MCWLs broad role in competitive funding of meritorious research across a spectrum of science and engineering disciplines.	Proposals accepted on a rolling basis until 9/30/21	Dependent upon proposal	https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements
81.	Broad Agency Announcement (BAA) Science & Technology for Advanced Manufacturing Projects (STAMP) (Dod/Navy)	N00014-21-S-B002	The Manufacturing Technology Program (ManTech) is the Defense Department's investment mechanism for staying at the forefront of defense-essential manufacturing capability. The ManTech Program targets the needs of our warfighters and weapon system programs by helping to find and implement affordable low-risk solutions. The focus of this BAA is primarily on projects that continue to advance the systems engineering approach needed for the design, fabrication, and manufacture of structural components to address challenges in system weight, performance, affordability, and/or survivability.	Proposals accepted on a rolling basis until 10/30/21	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=329699 (Full Announcement in Related Documents Tab)
82.	FY21 Funding Opportunity Announcement (FOA) for the Office of Naval Research (ONR) Science, Technology, Engineering and Mathematics (STEM) Program (Dod/Navy)	N00014-21-S-F005	The Office of Naval Research (ONR) seeks a broad range of applications for augmenting existing and/or developing innovative solutions that directly maintain and/or cultivate a diverse, world-class Science, Technology, Engineering and Mathematics (STEM) workforce to maintain the U.S. Navy and Marine Corps' technological superiority. The goal of proposed efforts must provide solutions that establish, build, and/or maintain STEM educational pathways and workforce opportunities for diverse U.S. citizens directly relevant to ONR science and technology areas.	Proposals accepted on a rolling basis until 3/30/22	Dependent upon proposal	https://www.onr.navy.mil/-/media/Files/Funding-Announcements/BAA/2021/N00014-21-S-F005.ashx

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			OMICS (1)			
83.	Feasibility Studies that Explore Healthy and Diseased Temporomandibular Joints (TMJ) using Single Cell Multi-Omic Analyses (UH2/UH3 Clinical Trial Not Allowed) (NIH/NIDCR)	RFA-DE-22-005	The purpose of this FOA is to encourage feasibility and discovery studies focused on providing foundational knowledge to further studies of cellular and molecular mechanisms underpinning temporomandibular joint disorders (TMJD) pain and tissue dysfunction using single-cell omics approaches. This FOA has goals of identifying cell populations and mapping their effector pathways in TMJD target tissue as 1) molecular disease classifiers allowing for patient stratification, 2) diagnostic, prognostic, and/or predictive biomarkers, and/or 3) novel therapeutic targets. The UH2 phase of this FOA will initially support a one-year milestone-driven planning and feasibility phase for all aspects of the clinical research study including planning for participant recruitment, sample collection and processing, and data analysis. The UH3 phase will provide support of up to two years for implementation of the study from human subjects recruitment to single cell data collection and analysis in line with the purpose of this FOA.	Letter of intent due: 10/10/21 Proposal due: 11/10/21	Up to $250,000, for up to 3 years (UH2) Up to $750,000, for up to 2 years (UH3)	https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-22-005.html
			OSTEOPOROSIS (1)			
84.	Comparative Effectiveness of Multimodal Interventions to Prevent Osteoporotic Fractures – Cycle 3 2021 (PCORI)	N/A	This Targeted PCORI Funding Announcement seeks to fund high-quality, comparative effectiveness research projects that focus on multimodal interventions to prevent fractures in people with osteoporosis and a history of a fracture. Applications should respond to the following question: What is the comparative effectiveness of multimodal treatment approaches on patient-centered outcomes in people with osteoporosis and a history of fractures? Proposed studies should compare the effectiveness of pharmacological and/or nonpharmacological combination interventions. PCORI is interested in comparing combinations and/or sequences of interventions that are either in common use, have suggested efficacy, or have strong theoretical underpinnings.	Letter of intent due: 10/5/21 Proposal due: 1/11/22	Up to $10 million, for up to 5 years	https://www.pcori.org/funding-opportunities/announcement/multimodal-interventions-prevent-osteoporotic-fractures-cycle-3-2021

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			PATIENT-CENTERED RESEARCH (9)			
85.	Engagement Award: Capacity Building -- October 2021 Cycle (PCORI)	N/A	This funding announcement offers an opportunity for organizations and community groups to build capacity and skills for patient-centered outcomes research and comparative clinical effectiveness research (PCOR/CER). PCORI is receptive to applications to the Engagement Award: Capacity Building encompassing a wide range of research support project topics. This opportunity aims to support projects that help communities increase their facility with and ability to participate across all phases of the PCOR/CER process. Within this announcement, we express two special areas of interest: (1) intellectual and developmental disabilities and (2) maternal morbidity and mortality.	Letter of intent due: 10/1/21 Proposal due: 1/10/22 (Invitation only)	Up to $250,000, for up to 2 years	https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-october-2021-cycle
86.	Engagement Award: Dissemination Initiative -- October 2021 Cycle (PCORI)	N/A	The dissemination of research findings to targeted end users is an important part of promoting the uptake of these findings into policy and practice. In many cases, the role of a "trusted source" in raising awareness of new evidence or placing it in an appropriate context is critical to enabling the uptake of this evidence into practice. This Engagement Award initiative focuses on supporting organizations that are trusted sources for their patient, professional, or other community, to undertake dissemination activities. Applicants for an Engagement Award: Dissemination Initiative will be required to focus their project on one of two tracks—Building Capacity for Dissemination or Active Dissemination—and will self-select the focus at the time of LOI submission.	Letter of intent due: 10/1/21 Proposal due: 1/10/22 (Invitation only)	Up to $250,000, for up to 2 years	https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-october-2021-cycle
87.	Engagement Award: Stakeholder Convening Support -- October 2021 Cycle (PCORI)	N/A	Through this award, PCORI seeks to fund projects designed by organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. These convenings must have a focus on, and commitment to, supporting collaboration around PCOR/CER. Convenings supported under this funding opportunity should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations. Within this announcement, we express three special areas of interest: (1) consideration of the full range of outcomes data, (2) intellectual and developmental disabilities, and (3) maternal morbidity and mortality.	Letter of intent due: 10/1/21 Proposal due: 1/10/22 (Invitation only)	Up to $100,000, for up to 1 year	https://www.pcori.org/funding-opportunities/announcement/engagement-award-stakeholder-convening-support-october-2021-cycle

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			PATIENT-CENTERED RESEARCH			
88.	Broad PCORI Funding Announcements -- Cycle 3 2021 (PCORI)	N/A	The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA covers the following four priority areas: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Health Systems. In addition to these four priority areas, PCORI's 2019 reauthorizing legislation provided additional direction about national research priorities to include research with respect to intellectual and developmental disabilities and to maternal mortality. Beginning Cycle 3 2021, PCORI has identified two Special Area of Emphasis (SAEs) to support innovative, high-impact studies that fit clearly within our core mission of patient-engaged and patient-centered comparative clinical effectiveness research. These SAEs are Telehealth for Chronic Disease Management among Vulnerable Populations with Complex Needs and Addressing Racism, Discrimination, and Bias in Healthcare Systems and Care Delivery.	Letter of intent due: 10/1/21 Proposal due: 1/10/22 (Invitation only)	Up to $5 million for up to 5 years, dependent upon proposal and award mechanism	https://www.pcori.org/funding-opportunities/announcement/broad-pcori-funding-announcements-cycle-3-2021
89.	Improving Methods for Conducting Patient-Centered Outcomes Research -- Cycle 3 2021 (PCORI)	N/A	PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by PCOR/CER studies. The programmatic priority for artificial intelligence and machine learning replaced the priority for "Methods to Improve the Use of Natural Language Processing (NLP)" as of Cycle 3 2020. This change signals PCORI's broader interest in funding methodological research that seeks to improve how massive amounts of data from a variety of sources can be: (1) appropriately analyzed and integrated into clinical care and health care delivery systems, and (2) facilitate population health models and social determinants of health analyses. Proposals should address mechanisms seeking to improve equitable, inclusive data collection and aggregation. NLP-related proposals will still be considered.	Letter of intent due: 10/1/21 Proposal due: 1/10/22 (Invitation only)	Up to $750,000, for up to 3 years	https://www.pcori.org/funding-opportunities/announcement/improving-methods-cycle-3-2021

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			PATIENT-CENTERED RESEARCH			
90.	Phased Large Awards for Comparative Effectiveness Research -- Cycle 3 2021 (PCORI)	N/A	This PCORI Funding Announcement (PFA) invites applications for high-quality, comparative effectiveness research projects that will examine a critical patient-centered research question that is also relevant to decision makers and other stakeholders. For this PFA, investigators should propose an individual-level or cluster randomized controlled trial of significant scale and scope. The proposed trials should address critical decisional dilemmas that require important new evidence about the comparative effectiveness of available interventions. Proposed studies should compare interventions that already have established evidence of efficacy or are in widespread use. Clinical interventions (such as medications, diagnostic tests, or procedures) and delivery system interventions are appropriate for these studies.	Letter of intent due: 10/5/21 Proposal due: 1/11/22	Phase I: Up to $2 million for up to 18 months Phase II: Up to $20 million for up to five years	https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-cycle-3-2021
91.	Limited PCORI Funding Announcement: Implementation of PCORI-Funded Patient-Centered Outcomes Research Results -- Cycle 3 2021 (PCORI)	N/A	The intent of this limited PFA is to move evidence developed with PCORI research funding toward practical use in improving health care and health outcomes. PCORI will fund projects that aim to implement patient-centered clinical comparative effectiveness research (CER) results obtained from PCORI-funded studies in real-world practice settings, and, in selected cases, projects that focus on the dissemination of these findings.	Letter of intent due: 9/28/21 Proposal due: 12/7/21	Dependent on proposal and award mechanism	https://www.pcori.org/funding-opportunities/announcement/limited-PFA-implementation-pcor-results-cycle-3-2021
92.	Implementation of Effective Shared Decision Making Approaches in Practice Settings -- Cycle 3 2021 (PCORI)	N/A	This PFA is intended to promote the targeted implementation and systematic uptake of shared decision making (SDM) in healthcare settings, in line with PCORI's goal of supporting patients in making informed decisions about their care. For this PFA, PCORI defines an SDM strategy as an intervention or approach that draws on and presents evidence to inform patients of available treatment options and their risks and benefits, and either engages patients in a decision-making process with their clinician or promotes their ability to engage in such a process.	Letter of intent due: 9/28/21 Proposal due: 12/7/21	Up to $1.5 million, for up to 3 years	https://www.pcori.org/funding-opportunities/announcement/implementation-effective-shared-decision-making-cycle-3-2021

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			PATIENT-CENTERED RESEARCH			
93.	Implementation of Findings from PCORI's Major Research Investments -- Cycle 3 2021 (PCORI)	N/A	PCORI seeks to fund implementation projects that incorporate active, multicomponent strategies that will lead to uptake and integration of PCORI-funded evidence in real-world practice settings. Implementation strategies should target specific end-users with a clear interest in—and who are able to benefit from—the evidence. Proposed implementation projects will adapt findings as needed to facilitate uptake in the proposed settings and accomplish scale-up (to reach larger numbers) and/or scale-out (to reach broader audiences, including diverse populations and settings).	Letter of intent due: 9/28/21 Proposal due: 12/7/21	Up to $2.5 million, for up to 3 years	https://www.pcori.org/funding-opportunities/announcement/implementation-findings-pcori-major-research-investments-cycle-3-2021
			PUBLIC HEALTH (1)			
94.	Partnership for Enhanced Efforts To Strengthen The Nation's Healthcare And Public Health Preparedness, Response, And Recovery To Disasters And Other Emergencies (HHS/ASPR)	EP-HIT-21-004	Throughout the COVID-19 response, ASPR discovered a variety of areas and lessons learned where it needs to strengthen and enhance its relationships to be able to leverage public health and healthcare partners to support timely and informed decision making and meet the need of an "all of nation" response to the current pandemic and future emergency incidents. Key areas include capabilities to: enhance domestic and international disease surveillance technology; continual assessment of ongoing response impacts, gaps, and the assessment of immediate and future resource needs; quick access to the nation's public health and healthcare frontline to convey timely and accurate information; and sharing of established and implemented best practices from the field.	Proposal due: 9/22/21	Up to $4 million per year, for up to 5 years	https://www.grantsolutions.gov/gs/preaward/previewPublicAnnouncement.do?id=94910

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			SICKLE CELL DISEASE (2)			
95.	Pre-Announcement: HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required/ Optional) (NIH)	NOT-AT-21-017 NOT-AT-21-018	The NIH HEAL Initiative intends to publish a FOA to support multisite pragmatic or implementation trials to inform the uptake of non-opioid pharmacologic and nonpharmacologic approaches for acute and chronic sickle cell disease (SCD) pain management in health care systems that serve the SCD population. Trials supported under this initiative would address the impact of these approaches on related psychological and functional outcomes to support improved overall well-being and quality of life, and also address social and structural barriers such as stigma and racial bias to SCD pain management care.	Estimated post date: 10/15/21 Estimated due date: 12/15/21	Up to $500,000, for up to 1 year (UG3) Up to $1 million, for up to 4 years (UH3)	https://grants.nih.gov/grants/guide/notice-files/NOT-AT-21-017.html https://grants.nih.gov/grants/guide/notice-files/NOT-AT-21-018.html
			SMALL BUSINESS DEVELOPMENT (1)			
96.	Joint DoD SBIR 21.3 / STTR 21.C Program Broad Agency Announcement (DoD)	DoD SBIR 21.3 and DoD STTR 21.C	The objectives of the DoD SBIR Program include stimulating technological innovation, strengthening the role of small business in meeting DoD research and development needs, fostering and encouraging participation by minority and disadvantaged persons in technological innovation, and increasing the commercial application of DoD-supported research or research and development results. Proposals accepted between 9/21/21 to 10/21/21. Click here to explore the full list of topic areas.	Proposal due: 10/21/21	Dependent upon award mechanism	https://rt.cto.mil/rtl-small-business-resources/sbir-sttr/
			SUBSTANCE ABUSE (11)			
97.	Mapping Patient Journeys in Drug Addiction Treatment (NIH Foundation)	N/A	The Challenge goal is to inspire the creation of actionable patient journey maps that might further the understanding of the obstacles that patients face in getting treatment for drug addiction, particularly while our country is in the middle of an ongoing opioid crisis. NIDA invites participants to identify specific points during the patient journey where patients encounter the most difficulty, enabling NIDA to focus new research efforts into alleviating those areas of difficulty in patients' drug addiction treatment journeys.	Proposal due: 9/22/21	Up to $50,000	https://www.challenge.gov/challenge/mapping-patient-journeys-in-drug-addiction-treatment/

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			SUBSTANCE ABUSE			
98.	Pre-Announcement: Grants to Support New Investigators in Conducting Research Related to Understanding Polydrug Use Risk and Protective Factors (CDC/NCIPC)	NCIPC	Applicants must propose a research project that aims to better understand and identify risk and protective factors related to polydrug initiation, use, and escalation and potential moderators of the associations, and the relationship between polydrug use and overdose, particularly among populations experiencing disproportionate burden of illicit substance use and overdose and/or who have experienced: Adverse childhood experiences; Chronic pain and/or pain for which they received treatment with prescription opioid analgesics; and/or Suicidal ideation or suicide attempts.	Estimated post date: 10/15/21 Estimated proposal due date: 1/14/22	Up to $150,000	https://www.grants.gov/web/grants/view-opportunity.html?oppId=335598
99.	NOSI: International Research Collaboration on Drug Abuse and Addiction Research (NIH/NIDA)	NOT-DA-21-064	Five opportunities within this notice. The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the United States. Applications examining all areas of NIDA-supported research addressing the causes, consequences, treatment, recovery, and prevention of drug use, misuse, and addiction are encouraged. Projects may be conducted through newly formed or well-established partnerships between investigators in a U.S.-based institution and scientists working in another country. All NIH grant applications for research to be conducted outside the United States must establish that the proposal takes advantage of unique research opportunities in other countries, speeds scientific discovery, and advances U.S. health science.	Multiple deadlines; first available due date: 10/2/21	Dependent upon award mechanism	https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-064.html
100.	NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) (NIH/NIDA)	PAR-21-320	The objective of this FOA is to ensure that highly trained clinical scientists will be available in adequate numbers and in appropriate scientific areas to reduce the burden of substance use/substance use disorder, to identify emerging substance use crises, and to respond to shifts in emergent/urgent substance use events and related health consequences. To accomplish this objective, the NIDA Research Education Program for Clinical Researchers and Clinicians will support research experiences and courses for skills development in areas relevant to the NIDA mission. This FOA is intended to support research education activities that enhance the knowledge of substance use and substance use disorder research.	Letter of intent due: 10/15/21 2/15/22 7/10/22 Proposal due: 11/15/21 3/15/22 8/10/22	Up to $350,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-21-320.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			SUBSTANCE ABUSE			
101.	Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) (NIH/NIDA)	PAR-22-027	This FOA supports pilot, feasibility or exploratory research in priority areas in substance use epidemiology, prevention, and health services, including: 1) responses to sudden and severe emerging drug issues; 2) responses to emerging marijuana trends and topics related to the shifting policy landscape, related to imminent policy change; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities; 4) responses to unexpected and time-sensitive medical system issues; 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities that relate to drug abuse and access and provision of health care service; 6) partnerships between researchers and state or local organizations to support the evaluation of new local policies, programs, or practices in response to public health emergencies; 7) research examining how the COVID-19 pandemic has impacted drug markets and overdose risk.	Letter of intent due: 12/11/21 4/3/22 8/8/22 Proposal due: 1/11/22 5/3/22 9/8/22	Up to $275,000, for up to 2 years	https://grants.nih.gov/grants/guide/pa-files/PAR-22-027.html
102.	Collaborative Partnership between Research Centers in Minority Institutions (RCMI) and Alcohol Research Centers (U54 Clinical Trial Optional) (NIH/NIAAA)	RFA-AA-21-015	This FOA encourages the planning and implementation of collaborative partnerships between RCMI and institutions with extensive alcohol research programs. The long-range goal of the collaborative partnership program between RCMI and ARC is to strengthen the alcohol research capacity, develop research expertise in biomedical and clinical fields to identify, characterize, and reduce adverse health effects due to alcohol use and misuse.	Letter of intent due: 11/15/21 Proposal due: 12/15/21	Up to $750,000 per year, for up to 5 years	https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-015.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			SUBSTANCE ABUSE			
103.	Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional) (NIH/NIDA)	RFA-DA-22-022	The purpose of this UG3/UH3 Phased Innovation Award Funding Opportunity Announcement is to support research to understand and respond to the new challenges in treating drug addiction and overdose, introduced by the presence of fentanyl and its analogs (fentanyls) in illicit drug supplies. Applications should focus on understanding and treating opioid and polydrug use disorders (including overdose), wherein fentanyls are a major contributor and their presence has altered previous estimations of the scope, impact and treatment of the problem. The research may include preclinical, clinical, epidemiological or even post-mortem studies. Studies should have high significance in order to quickly yield improvements in understanding and to provide effective responses to the problems caused by illicit fentanyls.	Letter of intent due: 9/19/21 Proposal due: 10/19/21	Up to $500,000, for up to 2 years (UG3) Up to $1 million, for up to 3 years (UH3)	https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-022.html
			TRAUMATIC BRAIN INJURY (7)			
104.	Clinical and Biological Measures of TBI-related Dementia Including Chronic Traumatic Encephalopathy (R01 Clinical Trial Not Allowed) (NIH/NINDS/ NIA)	PAR-22-024	This FOA invites investigation of biological and clinical measures of TBI-related progressive neurodegeneration and neurocognitive decline associated with increased risk for dementia and /or traumatic encephalopathy syndrome (TES) (clinicopathologic diagnostic counterpart to the neuropathological diagnosis of Chronic Traumatic Encephalopathy (CTE)). Investigations should be based on existing, well-characterized populations of patients with a history of TBI that are enriched for increased risk of cognitive impairment or dementia and can continue to be followed longitudinally; additional subjects may be recruited as appropriate. The overall goal is to advance knowledge of the underlying pathophysiology and clinical characterization of the chronic effects of TBI that distinguish static-chronic TBI cognitive impairment from those that lead to progressive neurodegeneration associated with TES and dementia. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data and to create a data and associated biofluid resource for the broader community to further advance research in this area.	Letter of intent due: 10/10/21 Proposal due: 11/10/21	Up to $1 million per year, for up to 5 years	https://grants.nih.gov/grants/guide/pa-files/PAR-22-024.html

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			TRAUMATIC BRAIN INJURY			
105.	Traumatic Brain Injury and Psychological Health Research Program (DoD/CDMRP)	W81XWH-21-S-TBIPH1; TBIPH2 W81XWH-21-TBIPHRP-IDA; IIRA; TRA; CDRA	The FY21 TBIPHR solicits research applications addressing at least one of the Focus Areas described below through six different award mechanisms: • Clinical Trial (W81XWH-21-S-TBIPH1) • Focused Program (W81XWH-21-S-TBIPH2) • Idea Development (W81XWH-21-TBIPHRP-IDA) • Investigator-Initiated Research (W81XWH-21-TBIPHRP-IIRA) • Translational Research Awards (W81XWH-21-TBIPHRP-TRA) • Clinical Research Development (W81XWH-21-TBIPHRP-CRDA) The Focus Areas broadly include the following but not all of which will be applicable to every award mechanism: 1) Knowledge gaps in foundational science, epidemiology, and etiology of TBI and psychological health, 2) Prevention or progression of TBI or psychological health conditions through population, selective, and indicated prevention approaches. Efforts that focus on primary prevention (including protection), screening, diagnosis, and prognosis are within scope, 3) Immediate and long-term treatments and improvements in systems of care, including access to and delivery of health care services. Treatment topics may include novel treatments and interventions, personalized medicine approaches, length and durability of treatment, rehabilitation, relapse, and relapse prevention.	Pre-application due: 9/22/21 Proposal due: 10/7/21 (Invitation only) (CDRA, IDA, IIRA) Pre-application due: 11/1/21 Proposal due: 12/16/21 (Invitation only) (CTA, FPA, TRA)	Up to $8 million, for up to 4 years Dependent upon award mechanism	https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-CRDA.pdf https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-CTA.pdf https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-FPA.pdf https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-IDA.pdf https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-IIRA.pdf https://cdmrp.army.mil/funding/pa/FY21-TBIPHRP-TRA.pdf https://cdmrp.army.mil/funding
			US AIR FORCE ACADEMY (1)			
106.	Research Interests of the United States Air Force Academy (DoD/Air Force)	USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. Research would essentially reveal mechanisms of existing natural systems, methods to incorporate present biological materials in nature, or disclose new capabilities within existing systems and/or materials.	Proposals accepted on a rolling basis	Dependent upon proposal, for up to 5 years	https://www.grants.gov/web/grants/view-opportunity.html?oppId=330175 (Full Announcement in Related Documents Tab)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			US ARMY COMBAT CAPABILITIES DEVELOPMENT COMMAND (1)			
107.	US Army Combat Capabilities Development Command Broad Agency Announcement (DoD/Army)	W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. This posting is not for a specific requirement - only to post the BAA solicitation so that interested parties can submit white papers and proposals for grants and other assistance agreements.	Proposals accepted on a rolling basis until 2/28/25	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285 (Full Announcement in Related Documents Tab)
			US ARMY RESEARCH INSTITUTE (2)			
108.	U.S. Army Research Institute for the Behavioral and Social Sciences (ARI) Broad Agency Announcement for Basic, Applied, and Advanced Research (DoD/Army)	W911NF-18-S-0005	Programs funded under this BAA include basic research, applied research, and advanced technology development that can improve human performance and Army readiness. Topic areas of basic research interest include: Understanding Team Dynamics; Improving Leadership and Leader Development; Identifying, Assessing, and Assigning Quality Personnel; Enhancing Lifelong Learning. ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology.	No due dates, open until 4/29/23 Full proposal required	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=304462 (Full Announcement in Related Documents Tab)
109.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic Scientific Research, Foundational Science Research Unit (2021-2022) (DoD/Army)	W911NF-21-S-0007	The U.S. Army Research Institute for the Behavioral and Social Sciences is the Army's lead agency for the conduct of research, development, and analyses for the improvement of Army readiness and performance via research advances and applications of the behavioral and social sciences that address personnel, organization, training, and leader development issues. Programs funded under this BAA include basic research that can improve human performance and Army readiness. Domains of interest include 1) Personnel Testing & Performance, 2) Learning in Formal and Informal Environments, 3) Organizational Effectiveness and 4) Leader Processes and Measurement.	White papers accepted until: 5/15/22 Proposals accepted until: 8/4/22	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=331391 (Full Announcement in Related Documents Tab)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			US MILITARY ACADEMY (1)			
110.	United States Military Academy Broad Agency Announcement (DoD/USMA)	W911NF-20-S-0008	This BAA identifies topics of interest to USMA departments, directorates, and research centers and institutes. The groups fund a modest amount of extramural research in certain specific areas, and those areas are described in this BAA. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies.	Proposals accepted on a rolling basis	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=325932 (Full Announcement in Related Documents Tab)
			US NAVY (2)			
111.	FY21 Naval Air Warfare Center Aircraft Division (NAWCAD) Office-Wide Broad Agency Announcement (DoD/Navy)	N0042121S0001	The NAWCAD is interested in receiving proposals for research and development projects, which offer potential for advancement and improvement of NAWCAD operations. NAWCAD has identified the research needed to address the challenges, problems, and future technology needs of the Warfighter. Research Opportunity Areas of Interest: Artificial Intelligence/Machine Learning, Data Science & Visualization, Cyber, Quantum, Hypersonic Systems, Test and Evaluation Engineering, Avionics, Sensors & Electronic Warfare, Secure Communications & Networks, Warfare Analysis, Readiness & Sustainment, Materials & Aircraft Structures, Aeromechanics, Mechanical Systems, Power & Propulsion Systems, Human Systems, Support Equipment, & Systems Engineering.	White papers accepted on a rolling basis until: 6/2/22 Proposal solicited by invitation	Dependent upon proposal	https://sam.gov/opp/3a0e0f16bedb42db830347d2c18fc9e9/view
112.	C4ISR, Information Operations, Cyberspace Operations and Information Technology System Research, Cryogenics & Quantum (DoD/Navy)	N66001-21-S-4700	The Naval Information Warfare Center, Pacific is soliciting white papers and proposals in accordance with FAR. Submissions in response to this announcement shall be for areas relating to the advancement of Command, Control, Communications, Computers, Intelligence, Surveillance, and Reconnaissance (C4ISR) capabilities, enabling technologies for Information Operations and Cyberspace Operations, and Information Technology systems. Accordingly, proposals selected for award are the result of full and open competition and fully compliant with PL 98-369, "The Competition in Contracting Act of 1984." This BAA is for procurement contracts (hereinafter referred to as contracts), grants, cooperative agreements, and other transactions. Proposed research should investigate unique and innovative approaches for defining and developing next generation integratable C4ISR capabilities and command suites.	White papers accepted on a rolling basis until: 6/4/22	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=334026 (Full Announcement in Related Documents Tab)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			USAMRDC EXTRAMURAL BAA (1)			
113.	USAMRDC Broad Agency Announcement for Extramural Medical Research (DoD/ USAMRDC)	W81XWH18SBAA1	This BAA supports extramural R&D ideas for basic and applied research to support scientific study and experimentation directed toward advancing the state of the art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution. R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease Research Program; Combat Casualty Care Research Program; Military Operational Research Program; Clinical and Rehabilitative Medicine Research Program; Medical Biological Defense Research Program; Medical Chemical Defense Research Program; Medical Simulation and Information Sciences Research Program.	No due dates, open until 9/30/22 Pre-application Required Full Proposal by invitation	Dependent upon proposal, for up to 5 years	https://www.grants.gov/web/grants/view-opportunity.html?oppId=297726 (Full Announcement in Related Documents Tab)
			USSOCOM EXTRAMURAL R&D (1)			
114.	Dept. of the Army, USAMRAA – BAA for Extramural Biomedical Research and Development (DoD/ USAMRAA)	W81XWH-18-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) for early intervention in life-threatening injuries, prolonged field care, human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. Equipment must be easy to use, require minimum maintenance, and have low power consumption. Drugs and biologics should not require refrigeration or special handling. All materiel and related techniques must be simple and effective, and easily modified for commercialization. Projects may apply existing knowledge for which concept and/or patient care efficacy have already been demonstrated to meet SOF requirements.	Proposals accepted through 7/31/23 Submission of a pre-proposal is required	Dependent upon proposal	https://www.grants.gov/web/grants/view-opportunity.html?oppId=307754 (Full Announcement in Related Documents Tab)

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			WARFIGHTER MEDICAL OPTIMIZATION DIVISION (1)			
115.	Airman Readiness Medical Research (ARMR) Hybrid BAA (DoD/Air Force)	FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance.	White papers accepted on rolling basis until 4/30/26	Up to $49 million, per award	https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332 (Full Announcement in Related Documents Tab)